grant
Rewired Metabolism and Immunosuppression in MYCN-driven Neuroblastoma
Organization BAYLOR COLLEGE OF MEDICINELocation HOUSTON, UNITED STATESPosted 15 Aug 2024Deadline 31 Jul 2029
NIHUS FederalResearch GrantFY20250-11 years oldATRAAdoptive Cell TransfersAnabolismAntibodiesAntitumor ResponseAutomobile DrivingAutoregulationBiologyCAR T cellsCAR modified T cellsCAR-TCAR-TsCancer GenesCancer-Promoting GeneCancersCell BodyCell Communication and SignalingCell FunctionCell PhysiologyCell ProcessCell SignalingCellsCellular FunctionCellular Metabolic ProcessCellular PhysiologyCellular ProcessChemicalsChildChild YouthChildhood CancersChildren (0-21)Co-cultureCocultivationCocultureCoculture TechniquesComplexConsumptionCysteineCysteine MetabolismCysteine Metabolism PathwayDNA mutationDataDeath RateDependenceDevelopmentDiseaseDisease remissionDisorderDysfunctionEnergy-Generating ResourcesEnvironmentEnzyme GeneEnzymesEssential Amino AcidsFunctional disorderGeneralized GrowthGeneticGenetic ChangeGenetic defectGenetic mutationGoalsGrowthHalf-CystineHomeostasisHumanIFNImmuneImmune EvasionImmune Modulation TherapyImmune infiltratesImmune mediated therapyImmune responseImmunesImmunochemical ImmunologicImmunocompetentImmunologicImmunologicalImmunologicallyImmunologically Directed TherapyImmunologicsImmunosuppressionImmunosuppression EffectImmunosuppressive EffectImmunotherapyImpairmentInduction TherapyInterferonsIntermediary MetabolismIntracellular Communication and SignalingL-CysteineLiteratureMYCNMYCN geneMalignant Childhood NeoplasmMalignant Childhood TumorMalignant NeoplasmsMalignant Pediatric NeoplasmMalignant Pediatric TumorMalignant TumorMalignant childhood cancerMemoryMetabolicMetabolic ProcessesMetabolismMiceMice MammalsModelingModern ManMolecularMorbidityMorbidity - disease rateMurineMusMutationNEOADJNMYCNMYC GeneNeoadjuvantNeoadjuvant TherapyNeoadjuvant TreatmentNeural CrestNeuroblastomaNo Evidence of DiseaseNutrientOncogenesOncogenesisOncogenicOperative ProceduresOperative Surgical ProceduresOxidation-ReductionPathway interactionsPatientsPhenotypePhysiological HomeostasisPhysiopathologyProcessProgenitor CellsProgressive DiseaseRadiationRedoxRegulationRelapseRemissionResearchRetinoic AcidRoleSignal TransductionSignal Transduction SystemsSignalingStarvationSubcellular ProcessSupplementationSurgicalSurgical InterventionsSurgical ProcedureSurvival RateT cells for CART-Cell ActivationT-Cell ProliferationT-CellsT-LymphocyteTherapeutic InterventionTissue GrowthTrans Vitamin A AcidTransforming GenesTretinoinTretinoinumTumor CellVitamin A AcidWithholding Treatmentactivate T cellsadoptive cell therapyadoptive cellular therapyall-trans-Retinoic Acidall-trans-Vitamin A acidanti-tumor responsebiological signal transductionbiosynthesiscancer cell metabolismcancer immunologycancer in a childcancer in childrencancer metabolismcancer microenvironmentcell metabolismcellular metabaolismcessation of treatmentcheck point blockadecheckpoint blockadechemotherapychild with cancerchildhood malignancychimeric antigen T cell receptorchimeric antigen receptor (CAR) T cellschimeric antigen receptor Tchimeric antigen receptor T cellschimeric antigen receptor fusion protein T-cellschimeric antigen receptor modified T cellsdevelopmentaldisease riskdisorder riskdrivingenergy sourceexhaustionextracellulargenome mutationhigh riskhost responseimmune cell infiltrateimmune check point blockadeimmune checkpoint blockadeimmune competentimmune evasiveimmune modulatory therapiesimmune modulatory treatmentimmune regulation therapyimmune regulation treatmentimmune regulatory therapyimmune suppressionimmune suppressive activityimmune suppressive functionimmune system responseimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmune-modulation treatmentimmuno therapyimmunomodulation therapyimmunomodulation treatmentimmunomodulator therapiesimmunomodulator treatmentimmunomodulator-based therapiesimmunomodulatory biologicsimmunomodulatory therapiesimmunomodulatory treatmentimmunoregulatory therapyimmunoregulatory treatmentimmunoresponseimmunosuppressive activityimmunosuppressive functionimmunosuppressive responseimprovedinduction therapiesintervention therapykidsmalignancymetabolic engineeringmetabolism measurementmetabolomicsmetabonomicsmortalitymortality ratemortality ratiomouse modelmurine modelneoplasm immunologyneoplasm/cancerneoplastic cellnovelontogenyoxidation reduction reactionpathophysiologypathwaypediatric cancerpediatric malignancypharmacologicprogramsrecruitresistance to therapyresistant to therapysocial rolestem cellssurgerytherapeutic immunomodulationtherapeutic immunoregulationtherapeutic resistancetherapy resistantthymus derived lymphocytetrans-Retinoic Acidtranscriptomicstreatment cessationtreatment resistancetumortumor cell metabolismtumor immunologytumor metabolismtumor microenvironmenttumorigenesisyoungster
Description preview
PROJECT SUMMARY
Amplification of the oncogene MYCN drives high-risk progressive disease, resistance to therapy, and a poor
overall survival rate below 45% for high-risk neuroblastoma (NB) patients. Further, more than half of all high-risk
patients will relapse, and the post-relapse survival rate is only 10%. MYCN-driven NB tumors have poor immune…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click